Information  X 
Enter a valid email address

Creo Medical Group (CREO)

  Print      Mail a friend

Wednesday 01 August, 2018

Creo Medical Group

Result of General Meeting

RNS Number : 5083W
Creo Medical Group PLC
01 August 2018

1 August 2018

Creo Medical Group plc

("Creo" or the "Company")


Result of General Meeting


Creo Medical Group plc (AIM: CREO) is pleased to announce that, at the General Meeting held today, all resolutions were duly passed by means of a poll vote.  The total number of votes received for each resolution is set out below:


Resolution No.

Votes for

Votes against

Votes total

Votes withheld


63,639,528 (94.09%)


3,995,278 (5.91%)

67,634,806 (83.37%)



63,639,528 (94.09%)


3,995,278 (5.91%)

67,634,806 (83.37%)



63,639,528 (93.23%)

4,620,278 (6.77%)

68,259,806 (84.14%)




The Company confirms that, conditional on Admission becoming effective, it has allotted and issued 4,000,000 new Ordinary Shares pursuant to the EIS/VCT Placing. It is expected that the EIS/VCT Placing Shares will be admitted to AIM with effect from 8.00am tomorrow, 2 August 2018.


Further details regarding the Placing and the Placing Shares can be found in the announcement issued by the Company on 13 July 2018 and in the Circular posted to Shareholders on that same day, which are available to view on the Company's website: Capitalised terms used, but not defined, in this announcement shall have the same meaning as set out in the Circular.


Following Admission of the EIS/VCT Placing Shares, the Company's issued ordinary share capital will consist of 85,123,065 Ordinary Shares; no shares are held in treasury. The above figure of 85,123,065 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.


The Additional EIS/VCT Placing is conditional on receipt of the Additional VCT Advanced assurance by the Company. Whilst the Non EIS/VCT Placing is not conditional the receipt of the Additional VCT Advanced Assurance, the allotment and Admission of the Non EIS/VCT Shares cannot take place before the allotment of the Additional EIS/VCT Shares.


As the Additional VCT Advanced Assurance has not yet been obtained, the issue of the Additional EIS/VCT Shares and the Non EIS/VCT Shares has been delayed. Admission of the Additional EIS/VCT Shares and Non EIS/VCT Shares will occur on the third Business Day following receipt of Additional VCT Advanced Assurance.


In the event that the Additional VCT Advanced Assurance is not received before the Long Stop Date of 13 September 2018 (or at such time as HMRC has informed the Company that such approval will not be obtained), then the Additional EIS/VCT Placing will not complete, but the Non EIS/VCT Placing will complete, the Non EIS/VCT Shares will be issued and Admission of the Non EIS/VCT Shares will take place at latest on the Long Stop Date.




Creo Medical:

+44 (0)129 160 6005

Richard Rees


+44 (0)207 397 8900

Camilla Hume / Mark Connelly (NOMAD)

Michael Johnson / Russell Kerr (Sales)

FTI Consulting:

+44 (0)203 727 1000

Brett Pollard / Mo Noonan

[email protected]


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t